Benitec Biopharma Inc. (BNTC): Operating Cash Flow
-$16.52M
Year ended 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | -$16.52M | n/m | 2026-09-14, From 2025-07-01 |
| 2025-06-30 | -$23.59M | n/m | 2026-09-14, From 2024-07-01 |
| 2024-06-30 | -$19.40M | n/m | 2026-03-20, From 2023-07-01 |
| 2023-06-30 | -$18.01M | n/m | 2024-09-26, From 2022-07-01 |
| 2022-06-30 | -$15.90M | n/m | 2023-09-21, From 2021-07-01 |
| 2021-06-30 | -$12.83M | n/m | 2022-09-02, From 2020-07-01 |
| 2020-06-30 | -$7.54M | n/m | 2021-09-20, From 2019-07-01 |
| 2019-06-30 | $4.79M | n/a | 2020-09-23, From 2018-07-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | -$16.52M | n/m |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | -$51.77M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$67.85M | n/m |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | -$65.78M | n/m |
| PepGen Inc. (PEPG) | 2025-12-31 | -$81.64M | n/m |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | -$95.25M | n/m |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | -$42.09M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$171.27M | n/m |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | -$62.34M | n/m |
Compare BNTC, ANRO, LXRX, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗